Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)
China · Delayed Price · Currency is CNY 36.42
-0.27 (-0.74%)
At close: Feb 13, 2026
SHA:688062 Revenue
Mabwell (Shanghai) Bioscience had revenue of 464.67M CNY in the quarter ending September 30, 2025, with 1,717.41% growth. This brings the company's revenue in the last twelve months to 624.52M, up 268.62% year-over-year. In the year 2024, Mabwell (Shanghai) Bioscience had annual revenue of 199.78M with 56.28% growth.
Revenue (ttm)
624.52M
Revenue Growth
+268.62%
P/S Ratio
23.29
Revenue / Employee
441.05K
Employees
1,362
Market Cap
14.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 199.78M | 71.95M | 56.28% |
| Dec 31, 2023 | 127.84M | 100.11M | 361.03% |
| Dec 31, 2022 | 27.73M | 11.50M | 70.88% |
| Dec 31, 2021 | 16.23M | 10.92M | 206.03% |
| Dec 31, 2020 | 5.30M | -24.12M | -81.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.62B |
| Anhui Anke Biotechnology (Group) | 2.58B |
| Tibet Cheezheng Tibetan Medicine | 2.39B |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Sinocelltech Group | 1.89B |
| Inner Mongolia Furui Medical Science | 1.47B |
| Jinyu Bio-technology | 1.33B |
| Hualan Biological Vaccine | 976.44M |